Abstract

Hepatocyte growth factor (HGF) has mitogenic, morphogenic and anti-apoptotic activities on renal epithelial cells, and is a potential renotropin for renal regeneration. In chronic renal failure/fibrosis, HGF in the kidney declines in a manner reciprocal to the increase in transforming growth factor-beta (TGF-beta). Neutralization of HGF by the antibody leads to acceleration of renal failure/fibrosis, while HGF administration leads to remarkable attenuation, thus indicating the importance of the balance between HGF and TGF-beta in the pathogenesis and therapy of chronic renal failure. HGF is strongly considered as potential treatment for acute and chronic renal failure.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call